- Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective StudyEren Orhan Onder; Ozturk Mehmet Akif; Sonmez Ozlem Uysal; Oyan BasakAmerican Journal of Therapeutics, 2016, 23(6).
- The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysister Veer Emil; Mohammad Nadia Haj; Lodder Paul; Ngai Lok Lam; Samaan Mary; van Oijen Martijn G H; van Laarhoven Hanneke W MGastric Cancer, 2016, 19(3): 696-712.
- Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002)Shen, Lin; Liu, Dan; Li, Ning; Guo, Weijian; Liu, Tianshu; Li, Hongli; Li, Jiayi; Bai, Yuxian; Deng, Yanhong; Zhuang, Zhi-xiang; Sun, Meili; Fan, Qingxia; Zhao, Fuyou; Han, Liang; Xia, Zhenzhong; Wang, Jianming; Qi, Charlie; Xu, Li; Qian, Xueming; Germa, CarolineAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
期刊论文
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study
7阅读
